What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

The POC testing market is set to reach $40 billion by 2022.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

The POC testing market is set to reach $40 billion by 2022.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

The StiffnoGraph is our innovative point-of-care device that estimates arterial stiffness and the vitamin K status within 2 minutes. Arterial stiffness and vitamin K insufficiency are major risk factors for cardiovascular disease.  Arterial stiffness increases the risk of hypertension, myocardial infarction, heart failure, stroke and chronic kidney disease amongst others. Early detection can lead to better prevention and treatment options.

The StiffnoGraph has been tested in a clinical study approved by the Dutch Medical Ethics Committee. The results are reproducible and show a good correlation with Pulse Wave Velocity, the current standard measurement of arterial stiffness.

The StiffnoGraph is intended to be used by healthcare professionals, such as general practitioners, orthomolecular practitioners, sports physicians, naturopaths, alternative medicine practitioners, dieticians and physiotherapists, as a first screening tool in the cardiovascular risk assessment of their clients.

Measurement of:

  • Arterial stiffness (arterial condition)
  • Evaluation of vitamin K status
  • SpO2
  • Heart rate

Scientific proof:

  • Clinical studies approved by accredited Medical Ethics Committee
  • Clinical evaluation report
  • Protected by patent application WO2016/131993 A2
  • Technology based on numerous scientific publications

Includes:

  • Handbook with scientific background information on arterial stiffness and calcification, written by Prof. Dr. Vermeer
  • Leather Pouch
  • Luxury box
  • Lanyard

Warranty/service:

  • 3 years warranty
  • Workshops by VitaK

 

Head office:
Oxfordlaan 55
6229 EV Maastricht
The Netherlands
T: +31 (0)43 388 5926

Laboratories:
Oxfordlaan 70
6229 EV Maastricht
The Netherlands
E: info@vitak.com